# US 2019/0375856 A1 · ANTI-HtrA1 ANTIBODIES AND METHODS OF USE THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375856 A1
- Document ID: US20190375856A1
- Status: Published application
- Kind: A1
- Application number: 16/543,818
- Filed: 2019-08-19
- Published: 2019-12-12
- Earliest claimed: 2015-10-30
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Robert F. KELLEY; Daniel K. KIRCHHOFER; Joyce LAI; Chingwei V. LEE; Wei-Ching LIANG; Michael T. LIPARI; Kelly M. LOYET; Tao SAI; Menno VAN LOOKEREN CAMPAGNE; Yan WU; Germaine FUH
- Web page: https://patentgrep.com/patent/US20190375856A1

## CPC

- C07K 16/40: against enzymes
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/53: Hinge
- C07K 2317/55: Fab or Fab'
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

## Claims

### Claim 1

An isolated antibody that specifically binds HtrA1, wherein the antibody comprises a binding domain comprising at least one of the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SYIMS (SEQ ID NO: 39);
(b) an HVR-H2 comprising the amino acid sequence of YISNGGGTTYYSDTIKG (SEQ ID NO: 40);
(c) an HVR-H3 comprising the amino acid sequence of QNFRSDGSSMDY (SEQ ID NO: 41);
(d) an HVR-L1 comprising the amino acid sequence of RASESVDSYGKSFMH (SEQ ID NO: 42);
(e) an HVR-L2 comprising the amino acid sequence of LASKLES (SEQ ID NO: 43); and
(I) an HVR-L3 comprising the amino acid sequence of QQNNEDPYT (SEQ ID NO: 44).

### Claim 2 (depends on 1)

The antibody according to claim 1, wherein the antibody comprises a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 45 and a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 46.

### Claim 3 (depends on 2)

The antibody according to claim 2, wherein the antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 45 and a VL domain comprising an amino acid sequence having the amino acid sequence of SEQ ID NO: 46.

### Claim 4 (depends on 1, 2, 3)

The antibody of any one of claims 1-3, wherein the antibody is monoclonal, humanized, or chimeric.

### Claim 5 (depends on 1, 2, 3, 4)

The antibody of any one of claims 1-4, wherein the antibody is an antibody fragment that binds to HtrA1.

### Claim 6 (depends on 5)

The antibody of claim 5, wherein the antibody fragment is selected from the group consisting of Fab, Fab′-SH, Fv, scFV, and (Fab′)2fragments.

### Claim 7 (depends on 6)

The antibody of claim 6, wherein the antibody fragment is a Fab.

### Claim 8 (depends on 7)

The antibody of claim 7, wherein the Fab comprises a truncation in the upper hinge of the heavy chain constant region.

### Claim 9 (depends on 8)

The antibody of claim 8, wherein the heavy chain constant region terminates at position 221 (EU numbering).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The antibody of any one of claims 1-9, wherein the antibody is a bispecific antibody.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

An isolated nucleic acid encoding the antibody of any one of claims 1-10.

### Claim 12 (depends on 11)

A method of producing an antibody, the method comprising culturing a host cell comprising a vector comprising an isolated nucleic according to claim 11 and recovering the antibody from the host cell or the host cell culture medium.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A pharmaceutical composition comprising an antibody of any one of claims 1-10 and further comprising at least one pharmaceutically acceptable carrier, excipient, or diluent.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A combination therapy comprising an antibody of any one of claims 1-10 and a Factor D antagonist, wherein the Factor D antagonist is an anti-Factor D antibody.

### Claim 15 (depends on 14)

The combination therapy of claim 14, wherein the anti-Factor D antibody is lampalizumab.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of treating an HtrA1-associated disorder or an ocular disorder in a human subject in need thereof, the method comprising administering a therapeutically effective amount of the antibody of any one of claims 1-10.

### Claim 17 (depends on 16)

The method of claim 16, wherein the HtrA1-associated disorder or the ocular disorder is age-related macular degeneration (AMD), diabetic retinopathy, retinopathy of prematurity, or polypoidal choroidal vasculopathy.

### Claim 18 (depends on 16, 17)

The method of claim 16 or 17, further comprising the step of administering a Factor D antagonist, wherein the Factor D antagonist is an anti-Factor D antibody.

### Claim 19 (depends on 18)

The method of claim 18, wherein the anti-Factor D antibody is lampalizumab.

### Claim 20 (depends on 16, 17, 18, 19)

The method of any one of claims 16-19, wherein the antibody is administered by a long-acting delivery system.

### Claim 21 (depends on 20)

The method of claim 20, wherein the long-acting delivery system is a PLGA-based solid implant or an implantable port delivery system.
